Equity, debt, and M&A advisory for healthcare and AI/technology companies at every stage of growth.
Equity is the most consequential form of capital a company will raise. The terms, the valuation, the investor syndicate, and the narrative that gets built around a company during a fundraise will follow it for years. We take that seriously. Our role is not simply to introduce companies to investors — it is to manage a competitive, structured process that maximizes optionality, preserves founder leverage, and results in the right capital from the right partners at the right time.
Most advisory firms treat fundraising as an introductions business. We treat it as a transaction management business. That means we spend as much time on positioning, materials, and investor targeting as we do on outreach. It means we prepare management for investor conversations the way a lawyer prepares a client for a deposition. And it means we do not declare success until the wire clears.
Non-dilutive capital is frequently underutilized by companies that are well-positioned to access it. When structured correctly, debt allows a company to extend runway, fund a commercial milestone, or bridge to a larger equity raise without surrendering equity at a moment when valuation has not yet reflected the company's full potential. The key is matching the right instrument to the company's stage, revenue profile, asset base, and covenant tolerance — and negotiating terms that do not create structural problems downstream.
We approach debt advisory with the same diligence we apply to equity. We assess the company's financial profile against the lender landscape, identify the instruments and providers most likely to close, and structure the mandate to give management the best possible terms. We also help clients understand the downstream implications of each structure — covenants, dilution provisions, repayment mechanics — so there are no surprises after the ink is dry.
A strategic transaction is the most complex and consequential event in most companies' histories. The difference between a well-run process and a poorly run one is often measured in tens of millions of dollars — and in whether the outcome reflects the company's true strategic value or the acquirer's opening offer. Lucent Growth advises management teams and boards through every phase of a strategic transaction, from initial positioning through final close.
For biotech and digital health companies, a pharma partnership or out-licensing arrangement is often as valuable — and as complex — as an outright acquisition. We advise on deal structure, term sheet negotiation, milestone and royalty architecture, and the strategic implications of exclusivity provisions. This is a specialized area, and we treat it with the same rigor as any other M&A mandate.
A structured methodology applied consistently across every engagement. Transparency, discipline, and accountability at every stage.
Every engagement begins with a structured diagnostic phase. We review the company's financial statements, cap table, competitive positioning, regulatory status, and existing investor relationships. We assess what the capital market will realistically support — in terms of valuation, structure, and investor type — and we give management an honest view of the opportunity and the gaps. If we identify issues that would impair a process, we raise them now. This phase typically takes two to three weeks and results in a Capital Strategy Memorandum outlining our recommended approach.
We build the full investor-grade package: an executive summary, an investor presentation (typically 20–30 slides), a detailed financial model with scenario analysis, a data room structure, and a company profile tailored to the investor audience. We approach materials the way a seasoned investor would read them — looking for gaps in the narrative, questions that aren't answered, and assumptions that won't hold up under scrutiny. Materials are revised until they are ready for institutional review, not just founder-comfortable.
We develop a targeted investor list specific to the mandate — sector focus, stage, check size, and current portfolio activity all factor into prioritization. We execute outreach through warm channels wherever possible and manage all investor communications centrally. Every introduction is preceded by a positioning conversation. We track the full pipeline — meetings scheduled, materials sent, follow-up status, data room access — and report to management on a weekly basis throughout the process.
The back half of a process is where most deals are won or lost. We manage term sheet evaluation, investor negotiation, and co-ordination through legal close. We advise management on the relative merits of competing terms, flag provisions that create downstream risk, and ensure the final documentation reflects the agreed commercial terms. We are present at every point of friction and advocate for our client's interests through to a clean, documented close.
Every engagement begins with a confidential, no-obligation conversation about your company and your capital needs.
Request a Confidential DiscussionAll initial discussions are strictly confidential and carry no obligation.